Radiopharm Theranostics (NASDAQ:RADX) Lowered to Strong Sell Rating by Wall Street Zen

Wall Street Zen cut shares of Radiopharm Theranostics (NASDAQ:RADX) to a strong sell rating in a report released on Friday morning.

Other equities analysts also recently issued reports about the stock. B. Riley reaffirmed a “buy” rating and set a $16.00 price objective (up from $13.00) on shares of Radiopharm Theranostics in a research note on Tuesday, December 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Radiopharm Theranostics in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Radiopharm Theranostics has a consensus rating of “Buy” and a consensus target price of $15.33.

Radiopharm Theranostics Stock Down 2.4%

Shares of NASDAQ RADX opened at $4.93 on Friday. The firm’s fifty day moving average is $5.02 and its 200 day moving average is $5.32. Radiopharm Theranostics has a 52 week low of $3.50 and a 52 week high of $16.25.

Institutional Trading of Radiopharm Theranostics

A hedge fund recently bought a new stake in Radiopharm Theranostics stock. PNC Financial Services Group Inc. bought a new position in Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor bought 8,000 shares of the company’s stock, valued at approximately $37,000. PNC Financial Services Group Inc. owned 0.10% of Radiopharm Theranostics at the end of the most recent reporting period.

Radiopharm Theranostics Company Profile

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.